Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-1401 in ulcerative colitis
NCT05743010Phase 1Unknown
- Sponsor
- Asieris Pharmaceuticals
- Start
- Jan 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing APL-1401 with Placebo (2 arms). Primary endpoints: Adverse Events, Serious Adverse Events and 1 more. Status: unknown.
02
Drugs
nepicastat
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05743010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05743010.